Sangamo submits ST-920 BLA clinical and preclinical modules to FDA for Fabry disease accelerated approval review
Reuters
Mar 09
Sangamo submits ST-920 BLA clinical and preclinical modules to FDA for Fabry disease accelerated approval review
Sangamo advanced its rolling BLA submission to the FDA seeking accelerated approval of ST-920 for adults with Fabry disease. The company said it has submitted the preclinical and clinical modules for FDA review. Sangamo also said its antibody assay companion diagnostic was submitted to and accepted by the FDA’s Center for Devices and Radiological Health for Premarket Approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603090805PRIMZONEFULLFEED9667691) on March 09, 2026, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.